Characteristics of japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: Based on the large-scale survey, FUTURE study

Internal Medicine

Volumn 50, Issue 20, 2011, Pages 2269-2276

  Kinoshita, Yoshikazu ^a   Chiba, Tsutomu ^b  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Endoscopy; Epigastralgia; Epigastric fullness; Izumo scale; Symptom

Indexed keywords

ABDOMINAL DISEASE; ADULT; ARTICLE; CHRONIC GASTRITIS; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DYSPEPSIA; EPIGASTRIC FULLNESS; FEMALE; FUNCTIONAL DISEASE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; JAPANESE; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RATING SCALE; RISK ASSESSMENT; RISK FACTOR;

CHRONIC DISEASE; DYSPEPSIA; FEMALE; GASTRITIS; HEALTH SURVEYS; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 80054753557     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5678     Document Type: Article

References (33)

1. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 45 Suppl 2: II37-II42, 1999.
2. Tack J, Talley NJ, Camilleri M, et al. Functional Gastroduodental Disorders. In: The Functional Gastrointentinal Disorders Third Edition. Printed by Allen Press Inc., Printed in the United States of America, 2006: 419-486.
3. Tack J, Tally NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 130: 1466-1479, 2006.
4. Tack J, Tally NJ. Gastroduodenal disorders. Am J Gastroenterol 105: 757-763, 2010.
5. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 3: 543-552, 2005.
6. Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 25: 1151-1156, 2010.
7. Locke GR, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 17: 29-34, 2005.
8. Manabe N, Haruma K, Hata J, et al. Clinical characteristics of Japanese dyspepsia patients: is the Rome III classification applicable? Scand J Gastroenterol 45: 567-572, 2010.
9. Furuta K, Ishihara S, Sato S, et al. Development and verification of the Izumo Scale, new questionnaire for quality of life assessment of patients with gastrointestinal symptoms. Nippon Shokakibyo Gakkai Zasshi (Japanese Journal of Gastroenterology) 106: 1478-1487, 2009 (in Japanese).
10. Furuta K, Ishihara S, Sato S, et al. Investigation of the responsiveness to a change in symptoms in the "Izumo scale," a questionnaire that assesses QOL in patients with gastrointestinal symptoms. Therapeutic Research 30: 1651-1657, 2009 (in Japanese).
11. Kinoshita Y. Investigation of the usefulness of the "Izumo scale," a QOL questionnaire on gastrointestinal symptoms. J New Rem & Clin 59: 192-201, 2010 (in Japanese).
12. Kakuta E, et al. Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med 50: 1517-1522, 2011.
13. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111: 85-92, 1996.
14. Shiota S, Murakami K. Endoscopic findings of dyspeptic patients. Clinical Gastroenterology 51: 467-470, 2010.
15. Talley NJ, Vakil NB, Moayyedi P, et al. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 129: 1756-1780, 2005.
16. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking lowdose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374: 119-125, 2009.
17. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 103: 2890-2907, 2008.
18. Ootani H, Iwakiri R, Shimoda R, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatroy drug use in bleeding peptic ulcers in Japan. J Gastroenterol 41: 41-46, 2006.
19. Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan Eur. J Clin Pharmacol 62: 765-772, 2006.
20. Kamata T, Yoneda M, Kawamoto H, et al. A study of gastric cancer mass screening using the serum pepsinogen test in combination with the barium X-ray method in Maniwa City, Okayama Prefecture. J Gastroenterological Cancer Screening 45: 514-521, 2007.
21. Kitagawa S, Miyagawa K, Utsunomiya S, et al. Gastroenterological Cancer Screening Report in 2008. The Japanese Society of Gastroenterological Cancer Screening Committee Report. J Gastroenterological Cancer Screening 49: 73-98, 2011.
22. Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 17: 1481-1491, 2003.
23. Kamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 18: 245-252, 2003.
24. Kato M, Watanabe M, Konishi S, et al. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 21 (Suppl. 2): 27-31, 2005.
25. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 21 (Suppl. 2): 32-36, 2005.
26. Kinoshita K, Hashimoto T, Kawamura A. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 21 (Suppl. 2): 37-41, 2005.
27. Meineche-Schmidt V, Christensen E, Bytzer P. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care-a randomised, placebo-controlled study. Aliment Pharmacol Ther 33: 41-49, 2011.
28. Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 116: 740-748, 2004.
29. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dosedependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 22: 618-625, 2010.
30. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebocontrolled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 21: 272-280, 2009.
31. Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroentero Hepato 22: 1566-1570, 2007.
32. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 354: 832-840, 2006.
33. Miwa H, Tomaga K, Yokoyama T, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 104: 2779-2787, 2009.